COMMUNIQUÉS West-GlobeNewswire

Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors

23/04/2025 - 14:00

HOUSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for [...]

Akoya Biosciences and Singapore Translational Cancer Consortium (STCC) Partner on SUPER Study Designed to Advance Cancer Immunophenotyping for Patients in Singapore

23/04/2025 - 14:00

The STCC Unified PD1/PDL1 Evaluation of Response (SUPER) study is a multi-institutional study led by STCC with the goal of identifying predictors of PD1 immunotherapy response in an Asian real-world setting, bringing [...]

Sanara MedTech to Report First Quarter 2025 Financial Results on May 14, 2025

23/04/2025 - 14:00

FORT WORTH, TX, April 23, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc . (“Sanara,” or the “Company”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to [...]

Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025

23/04/2025 - 14:00

SAN MATEO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and [...]

Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

23/04/2025 - 14:00

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced it will [...]

Daré Bioscience to Present at the Fierce Pharma Engage Summit on Breaking Barriers and Building Access: Communicating Bold Moves in Women’s Health Innovation

23/04/2025 - 14:00

Presentation will focus on corporate communications strategies for unveiling an innovative expanded business strategy Daré recently announced its new dual-path approach for its proprietary Sildenafil Cream formulation [...]

Rectify Pharma to Share Preclinical Data Highlighting Progress in Hepatobiliary Program at EASL 2025

23/04/2025 - 14:00

BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, Inc., (“Rectify”) a biotechnology company pioneering positive functional modulators (PFMs) that restore and enhance membrane protein function, today [...]

Arialief Reviews And Complaints (INVESTIGATIVE REPORT) Safe Ingredients for Neuropathy Relief or Over Hype?

23/04/2025 - 14:00

MIAMI, April 23, 2025 (GLOBE NEWSWIRE) -- Arialief is a nerve-support supplement that has recently seen a rise in popularity. Like many dietary supplements aimed at relieving sciatic discomfort, it claims to deliver [...]

Phathom Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide Business Update on Thursday, May 1, 2025

23/04/2025 - 14:00

• Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on [...]

ProDentim Complaints & Side Effects (EXPOSED) Investigative Consumer Report Examines Scientific Claims About ProDentim!

23/04/2025 - 05:55

AUSTIN, Texas, April 22, 2025 (GLOBE NEWSWIRE) -- ProDentim is a dental probiotic formula that fosters healthy teeth and gums by building a balanced ecosystem within the mouth. It addresses the root cause of oral [...]

Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers

23/04/2025 - 09:00

INGELHEIM, Germany and AMSTERDAM, April 23, 2025 (GLOBE NEWSWIRE) -- Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered [...]

Cytovation Raises US$6m to Advance Phase 2 Development of CY-101 in Adrenocortical Carcinoma to First Clinical Readouts

23/04/2025 - 09:00

New funds provided largely by existing investors, led by Sandwater Phase 2 trial to be delivered through novel agreement between Cytovation, Cancer Research UK and the Norwegian Cancer Society New preclinical data [...]

Antag Therapeutics expands senior team to support clinical progress

23/04/2025 - 09:00

Copenhagen, Denmark, 23 April 2025 – Antag Therapeutics (“Antag” or “the Company”), a biopharmaceutical company pioneering novel treatments for obesity, today announces the appointment of three new hires to support the [...]

Pharming receives positive recommendation from NICE for Joenja®▼(leniolisib) as a treatment for APDS

23/04/2025 - 09:30

For media and investors only Joenja® is the first and only medicine specifically for APDS to be reimbursed within the NHS Recommended for adult and pediatric patients 12 years of age and older with activated [...]

Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers

23/04/2025 - 09:30

Ingelheim, Germany and Amsterdam, the Netherlands, 23 April 2025 – Boehringer Ingelheim and Tessellate Bio, a precision oncology company with a focus on developing novel synthetic lethality approaches, have entered into [...]

Orion Group Interim Report January–March 2025

23/04/2025 - 11:00

ORION CORPORATION INTERIM REPORT 1–3/2025 23 APRIL 2025 at 12:00 EEST Orion Group Interim Report January–March 2025 January–March 2025 Highlights Net sales totalled EUR 354.6 (January–March 2024: 308.5) million [...]

Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS)

23/04/2025 - 07:00

Roche, in collaboration with Universitätsklinikum Heidelberg, has developed a Chest Pain Triage algorithm – a CE-marked IVD medical device 1 set to transform cardiac care This novel algorithm offers a standardised [...]

VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a Pipeline of Next-Generation Cancer Therapies

23/04/2025 - 07:09

VERAXA’s Novel BiTAC Platform has the Potential to Deliver Multiple Next-Generation Solid Tumor Cancer Therapies, Including Novel Antibody-Drug Conjugate ("ADC") and Bispecific T-cell Engager ("TCE") Candidates, with [...]

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

23/04/2025 - 08:01

Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company [...]